Dr Ivan Koychev is a Consultant Neuropsychiatrist at the Department of Psychological Medicine of Oxford University NHS Foundation Trust. He has a special interest in acquired brain injury, cognitive and movement disorders, and how digital technology can facilitate detection of risk for deterioration and support recovery.
- Senior Clinical Researcher, University of Oxford, 2019 – present
- National Institute for Health and Care Excellence Technology Assessment Committee member, 2021 – present
- Thames Valley Alzheimer’s Research UK board member 2021 – present
- Chief Medical Officer, Five Lives SAS (https://www.fivelives.health/), 2021 – present
In his NHS practice, Dr Koychev focuses on the assessment and management of patients presenting with psychiatric needs in the context of neurological or neurosurgical disorder. He works in an acute medical trust, seeing patients on acute and intensive care wards as well as outpatients. Dr Koychev provides neuropsychiatric inputs into disease specific multi-disciplinary teams: cognitive disorders, movement disorders, epilepsy, and neurofibromatosis.
Dr Koychev has a research interest in detection and intervention in preclinical Alzheimer’s disease. He is the Chief Investigator of the Impact of Semaglutide as part of which his team is testing whether a drug prescribed in diabetes can affect the processes underlying Alzheimer’s disease in ageing adults free of dementia. Dr Koychev leads the Dementias Platform UK Great Minds research volunteer network which supports targeted recruitment into brain health studies. He is a co-investigator on the RADAR AD study which tests the utility of digital technology to assess daily function across the dementia disease spectrum.
Academic Clinical Lecturer, University of Oxford, 2015 – 2019
Academic Clinical Fellow, King’s College London, 2012 – 2015
University Hospitals of Leicester NHS Foundation Trust, 2011-2012
DPhil Student, University of Manchester, 2008 – 2011